How Hot Melt Extrusion Partners Support Oral Drug Formulations

Poor solubility remains one of the most persistent challenges in oral drug development. An estimated 40% of marketed drugs and up to 90% of compounds in development pipelines fall into Biopharmaceutical Classification System (BCS) Class II or IV, meaning they have low solubility that limits how much active pharmaceutical ingredient (API) reaches systemic circulation. For pharmaceutical teams working to bring these molecules to patients, hot melt extrusion (HME) has emerged as a proven technology for improving bioavailability through amorphous solid dispersion (ASD) formulations.

But HME is not a commodity service. The difference between a successful commercial launch and a stalled program often comes down to partner selection. Pharmaceutical outsourcing decisions for HME require careful evaluation of a contract manufacturing organization's bioavailability expertise, scale-up capability, formulation support, and manufacturing reliability.

This article provides a framework for assessing HME partners across these four pillars.

Why Hot Melt Extrusion Matters for Oral Drug Formulations

Hot melt extrusion transforms crystalline APIs with poor solubility into amorphous solid dispersions. In this process, a powder blend of crystalline API and polymers is heated and extruded into a matrix where the API is dispersed evenly throughout the polymer. The resulting extrudate—typically converted into granules or pellets for downstream processing into tablets, capsules, or powder-filled sachets—delivers the API in a form that dissolves more readily in the gastrointestinal tract.

The benefits of HME for oral drug formulations include:

• Bioavailability enhancement: ASDs improve solubility and dissolution, increasing the amount of drug that enters circulation
• Efficient continuous processing: HME equipment has a small footprint and enables continuous manufacturing with high process understanding and control
• Solvent-free operation: Unlike spray drying, HME does not require solvents, simplifying environmental and safety considerations
• Uniform API distribution: The extrudate provides consistent drug distribution, which is essential for effective downstream processing

For BCS Class II and IV compounds, HME addresses a fundamental formulation challenge that can otherwise limit therapeutic efficacy or require higher doses to achieve target exposure.

Pillar 1: Bioavailability Expertise

The first criterion for evaluating an HME partner is depth of bioavailability expertise. This goes beyond equipment ownership to encompass scientific understanding of how API properties, polymer selection, and process parameters interact to determine final product performance.

What to assess:

• API characterization capabilities: Can the partner evaluate both physical and chemical properties of your API to determine HME feasibility? Look for proprietary techniques to estimate feasibility and success rates before committing to full development.
• Polymer expertise: Does the partner understand how different polymers affect manufacturability and final drug product properties? Polymer selection directly impacts stability, dissolution, and downstream processing.
• BCS classification experience: Has the partner successfully developed ASDs for compounds across BCS Class II and IV? Request case studies demonstrating bioavailability enhancement for molecules with similar solubility profiles.
• Analytical method development: Does the partner have robust analytical capabilities to characterize critical quality attributes including uniformity, moisture content, and degradation products?

Partners with extensive bioavailability expertise will have a structured approach to feasibility assessment. A stage-gated program that evaluates HME applicability before committing significant resources protects both parties and increases the probability of technical success.

Pillar 2: Scale-Up Capability

The transition from laboratory-scale development to commercial manufacturing is where many HME programs encounter delays. Scale-up capability requires not just larger equipment, but integrated process understanding that translates small-scale parameters to commercial-scale operations.

What to assess:

• Equipment range: Does the partner have GMP extruders spanning development through commercial scale? Look for screw sizes ranging from 18mm for clinical manufacturing to 70mm for commercial production.
• Multi-site flexibility: Can the partner offer manufacturing in multiple geographies to support global supply chain requirements and provide redundancy?
• Process development expertise: Does the partner have a defined methodology for establishing critical material properties (CMPs) and critical process parameters (CPPs) during scale-up?
• Design space definition: Can the partner optimize processes at commercial scale and define the design space to support regulatory filings?

The timeline from API characterization to clinical manufacturing is a key indicator of scale-up capability. Partners with integrated development and commercial manufacturing can typically reach clinical manufacturing in 6 to 12 months, depending on API complexity.

Pillar 3: Formulation Support

HME is one component of a broader formulation strategy. The right partner provides end-to-end formulation support from initial feasibility through final dosage form development.

What to assess:

• Stage-gated development process: Does the partner offer a clearly defined program with success criteria and the ability to opt out after each stage? This protects your investment while maintaining flexibility.
• Downstream manufacturing options: Can the partner support all associated final dosage forms? Look for capabilities in tablets, capsules, controlled release, and modified release formulations.
• Packaging integration: Does the partner offer integrated packaging services including blister, bottle, sachet/stick, and wallet configurations?
• Potent compound handling: If your API requires containment, does the partner have potent capability with appropriate occupational exposure limits?

Formulation support also includes regulatory strategy. Partners with experience filing HME products globally understand the CMC documentation requirements and can help position your submission for first-cycle approval.

Pillar 4: Manufacturing Reliability

Contract manufacturing services for oral drug formulations require consistent, reliable supply. Manufacturing reliability encompasses quality systems, regulatory compliance, and operational track record.

What to assess:

• Commercial track record: How many HME products has the partner successfully launched? Look for partners with multiple commercially approved products utilizing HME technology.
• Quality systems: Does the partner operate under integrated quality and regulatory systems with global approval experience?
• Inspection history: What is the partner's regulatory inspection track record across FDA, EMA, and other major health authorities?
• Supply chain integrity: Does the partner have redundancy in supply through multiple manufacturing sites?
• Confidentiality and IP protection: Does the partner have robust data handling, secure file sharing, and contractual protections for your intellectual property?

An embedded CMO—one that operates as part of a larger pharmaceutical organization—offers distinct advantages for manufacturing reliability. These partners use the same facilities, quality systems, and processes for client products as they do for their own drug products, ensuring consistent standards and operational excellence.

The Embedded CMO Advantage for HME

When evaluating pharmaceutical outsourcing options for HME, consider the structural differences between stand-alone CMOs and embedded CMOs.

Stand-alone CMOs operate on a capacity-filling model where they are fully reliant on incoming business. This can create pressure to over-commit and under-deliver. Embedded CMOs, by contrast, share in the success of a parent organization that is financially supported by its own drug products. This business model allows for:

• Selective partnering: The embedded CMO can choose projects that best fit its technologies and expertise rather than accepting every opportunity to fill capacity.
• Long-term investment: The parent organization's investment in maintaining global pharmaceutical leadership benefits CMO partners through access to current technologies and processes.
• Proven processes: Technologies and processes have been applied successfully to develop the parent company's own drugs before being offered to partners.
• Regulatory currency: Working knowledge of global regulatory requirements comes from having marketed products worldwide, translating to superior adaptability to evolving compliance expectations.

For HME specifically, an embedded CMO with its own portfolio of commercially approved HME products brings formulation and manufacturing expertise that has been validated through real-world commercial success.

Solid Dispersion Technology: A Closer Look

Understanding solid dispersion technology is essential for evaluating HME partners. An amorphous solid dispersion (ASD) is a distribution of drug molecules within a solid polymer matrix. Unlike crystalline forms, amorphous APIs have higher free energy and dissolve more readily, improving bioavailability.

The HME process creates ASDs through a combination of thermal and mechanical energy. Twin-screw extruders mix the API and polymer while the mechanical energy generated by the screws melts the mixture. The molten material is then pushed through a calendar roller and formed into a sheet of pellets—the extrudate—which is cooled and broken apart for downstream processing.

Key considerations for solid dispersion technology include:

• Physical stability: Amorphous forms can recrystallize over time, reducing bioavailability. Polymer selection and process optimization are critical for maintaining physical stability throughout shelf life.
• Chemical stability: The thermal processing involved in HME requires APIs that can withstand elevated temperatures without degradation.
• Moisture sensitivity: ASDs can be sensitive to moisture, requiring appropriate packaging and storage conditions.

Partners with deep solid dispersion technology expertise will have proprietary techniques for predicting stability and optimizing formulations to maintain the amorphous state.

Questions to Ask Potential HME Partners

When evaluating contract manufacturing services for HME, consider asking:

1. How many HME development programs have you completed, and how many have reached commercial manufacturing?
2. What is your typical timeline from API characterization to clinical manufacturing?
3. What extruder sizes do you have available for development and commercial manufacturing?
4. Can you provide case studies demonstrating bioavailability enhancement for BCS Class II or IV compounds?
5. What is your approach to technology transfer and scale-up?
6. How do you handle potent compounds requiring containment?
7. What downstream dosage form options do you support?
8. What is your regulatory inspection history?
9. How do you protect client intellectual property and confidential information?
10. What geographic flexibility do you offer for commercial manufacturing?

Conclusion

Selecting the right HME CDMO partner is a strategic decision that impacts program timelines, regulatory success, and ultimately patient access to needed therapies. By evaluating partners across the four pillars of bioavailability expertise, scale-up capability, formulation support, and manufacturing reliability, pharmaceutical teams can identify contract manufacturing organizations positioned to support successful development and commercialization of oral drug formulations.

The most capable HME partners combine decades of experience, proven commercial track records, and integrated capabilities that span from early feasibility through global commercial supply. For compounds with bioavailability challenges, the right partner transforms a formulation obstacle into a pathway to patients.